DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

Governs coverage and prior authorization for adjunctive laboratory and device-based tests (TissueCypher, EsoCheck/EsoGuard, BarreGEN) used to screen, surveil, or risk-stratify patients with or at risk for Barrett esophagus for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAdjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

Policy CodePolicy N/A

Change TypeMinor / no material change

Effective DateJul 1, 2025

Next Review DateMar 19, 2025

Key ActionObtain prior authorization for unlisted molecular pathology procedures (e.g., 81479) and document medical necessity before billing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3named tests addressed

0108U,0114U,81479codes referenced

No studiesBarreGEN evidence

multipleadjunctive technologies cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Tests considered not covered / not medically necessary for Medicare Advantage and Commercial Products unless otherwise specified:

EsoCheck / EsoGuard not covered: EsoCheck and EsoGuard for the screening and surveillance of Barrett esophagus and esophageal dysplasia are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

[[chunk 3]]

TissueCypher not covered: TissueCypher for assessing the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in individuals with Barrett esophagus is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

[[chunk 3, chunk 14]]

BarreGEN not covered: BarreGEN for assessing the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in individuals with Barrett esophagus is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.

[[chunk 3, chunk 14]]

Some genetic testing services may be contractually excluded for self-funded groups under the state's Biomarker Testing Mandate (R.I.G.L. §27-1981). Refer to the member's Benefit Booklet or plan documents to determine whether a specific service is excluded or subject to customized coverage for that member.

Coverage and benefits are governed by the member's subscriber agreement, member certificate, and/or the employer agreement. Those documents supersede the provisions of this medical policy; for member-specific coverage and eligibility, contact the provider call center.

The following tests are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products because evidence is insufficient to demonstrate improvement in net health outcome: EsoCheck/EsoGuard, TissueCypher, and BarreGEN.

Services determined to be not medically necessary (or classified as non-covered benefits) are not payable. Providers may not charge the member for such services unless the member has been informed in advance and has agreed in writing to assume financial responsibility.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage plans and is recommended for Commercial products. All unlisted genetic or molecular testing CPT codes (for example, 81479) require prior authorization to determine what service is being rendered and whether the service is covered or medically necessary.

Prior authorization obtained via the online tool for participating providers.
Unlisted CPT codes: 81479 (Unlisted molecular pathology procedure)

Note

Prior Authorization and Benefits Verification

Verify member-specific benefits and eligibility prior to providing services. Benefits and eligibility are determined by the member's subscriber agreement, member certificate, and/or employer agreement; contact the provider call center for verification. Services determined not to be medically necessary or not covered may be denied and the provider may not charge the member unless the member has provided written agreement in advance.

Contact provider call center for member-specific benefits and eligibility.
Do not bill the member for services denied as not medically necessary unless documented written agreement exists.

Billing Rule

Prohibition on Laboratory or Third-Party Authorization Assistance

If a laboratory or any third party assists in obtaining authorization, facilitates the authorization process, prepares documentation for clinical appropriateness, or participates in any appeal on behalf of the ordering physician, BCBSRI will deem this a violation of policy. Such actions may result in severe sanctions up to and including termination from the BCBSRI provider network. If a laboratory provides a laboratory service that has not been authorized, the service will be denied and the financial liability will fall on the participating laboratory; the service may not be billed to the member.

Laboratories and their representatives are prohibited from obtaining authorization or participating in the authorization or appeal process on behalf of the ordering physician.
Unauthorized laboratory services will be denied and the laboratory is financially responsible; cannot bill the member.

Documentation Required

Documentation for Unlisted CPT Codes

For services filed with an Unlisted CPT code (for example, 81479 for BarreGEN) prior authorization is required and providers must supply documentation establishing what service was performed and the medical necessity for that service. When an unlisted code is used, the medical necessity criteria in the Proprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA) policies will be applied as applicable.

All Unlisted genetic/molecular testing CPT codes require prior authorization to determine coverage and medical necessity.
Documentation must clearly describe the service rendered when an Unlisted CPT is billed.

Denial Risk

Denial Risk and Member Billing

Services determined to be not medically necessary or not covered under the member's benefit may be denied. Providers must follow authorization requirements and may not charge members for denied services except as allowed by the member's written advance agreement. Refer to participation agreements for additional billing obligations and restrictions.

Denials may result if authorization is not obtained or medical necessity is not met.
Providers may not charge members for non‑covered or not medically necessary services unless the member agreed in writing in advance.

Definitions and Key Terms

Barrett esophagus (BE) — Definition

DefinitionReplacement of esophageal squamous epithelium by specialized columnar intestinal-type epithelium in the distal esophagus confirmed by biopsy demonstrating intestinal metaplasia.

LocationOccurs in the distal esophagus; may be focal or circumferential and visualized on endoscopy by altered mucosal color.

Diagnostic requirementConfirmation requires endoscopic biopsy of columnar epithelium with microscopic identification of intestinal metaplasia.

Associated factorsAssociated with gastroesophageal reflux disease (GERD), male sex, central obesity, and age >50 years.

PrevalenceEstimated prevalence in the United States is approximately 5.6%.

High-grade dysplasia (HGD) — Definition

DefinitionA grade of dysplasia in Barrett esophagus associated with an estimated ~7% per year risk of progression to esophageal adenocarcinoma.

Management implicationEndoscopic eradication therapy is recommended for high-grade dysplasia; choice of procedure depends on age, comorbidities, extent of dysplasia, local expertise, and patient preference.

Clinical significanceApproximately 40% of patients with high-grade dysplasia on biopsy are found to have associated carcinoma in the resection specimen.

Adjunctive tests — Definition

DefinitionNonendoscopic sampling devices, molecular DNA assays, and tissue systems pathology risk classifiers used to augment endoscopic biopsy and histopathology for detection or risk stratification in Barrett esophagus.

ExamplesIncludes molecular DNA methylation assays (e.g., EsoGuard/EsoCheck), tissue systems pathology assays (e.g., TissueCypher), and genomic risk classifiers (e.g., BarreGEN).

PurposeIntended to improve detection, surveillance, or prognostic risk classification of Barrett esophagus beyond standard endoscopic biopsy and histology.

Evidence requirementAdoption requires demonstration of improved net health outcomes compared with standard care to be considered medically necessary.

OpenPayer

Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

Coverage Criteria — Adjunctive Tests for Barrett Esophagus

Coding and Billing

Provider Actions, Prior Authorization, and Documentation

Background

Definitions and Key Terms

0108U	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer (TissueCypher)
0114U	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus (EsoCheck/EsoGuard)